Loading clinical trials...
Loading clinical trials...
A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects With Advanced Non Central Nervous System Tumors That Are Amenable to Direct Injection
Conditions
Interventions
Talimogene Laherparepvec
Locations
22
United States
AI Dupont Hospital for Children
Wilmington, Delaware, United States
Nemours du Pont Hospital in Florida
Jacksonville, Florida, United States
Ann and Robert H Lurie Childrens Hospital of Chicago
Chicago, Illinois, United States
Riley Hospital for Children
Indianapolis, Indiana, United States
Childrens Hospital of Michigan
Detroit, Michigan, United States
Columbia University Medical Center
New York, New York, United States
Start Date
August 16, 2017
Primary Completion Date
January 17, 2022
Completion Date
November 29, 2022
Last Updated
February 20, 2024
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions